Claims for Patent: 9,504,603

Summary for Patent: 9,504,603

Title:	Intraocular delivery devices and methods therefor
Abstract:	Injection devices for delivering pharmaceutical compositions into the eye are described. Some devices include a resistance component for controllably deploying an injection needle through the eye wall. The resistance component may be disposed on the injector device, or on a portion of the injection device housing, or on a drug reservoir. Some devices may be removably attached to a drug reservoir, for example, through a luer connector. Other devices may comprise internal luer seal for securely connecting a drug conduit of the device to the luer cavity of a drug reservoir. Yet other devices may comprise a priming-enabling element to facilitate the drug priming of a shielded needle. Related methods and systems comprising the devices are also described.
Inventor(s):	Lerner; Leonid E. (Corona Del Mar, CA)
Assignee:	OcuJect, LLC (Newport Beach, CA)
Application Number:	14/047,476
Patent Claims:	1. An injector device for drug delivery comprising: a needle assembly, the needle assembly comprising: a needle hub comprising an input port on its proximal end for removable connection to a distal end of a syringe comprising a drug reservoir; a needle having a proximal portion, a distal portion, and an exit port on the distal portion, the proximal portion of the needle housed within the needle hub and a distal portion of the needle extending distally beyond the needle hub; and a resistance component comprising a cylindrical, rigid slidable sleeve comprising a cavity within the slidable sleeve and configured for axial movement and configured such that the needle is completely circumscribed by the slidable sleeve when the slidable sleeve is in a first, distal position with respect to the needle hub, and the distal portion of the needle extends distally beyond the slidable sleeve when the slidable sleeve is in a second, proximal position with respect to the needle hub, wherein the slidable sleeve has a proximal end, a distal end, and a constant sidewall having a fixed axial length and constant outer diameter when moved from the first position to the second position; and a priming-enabling component circumscribed by the slidable sleeve, the priming-enabling component located distal to the cavity and comprising a needle tunnel configured such that the needle can axially slide with respect to the needle tunnel, the needle tunnel comprising a first segment comprising a first diameter configured to prevent a solution from the drug reservoir from leaking from the exit port of the distal portion of the needle back proximally into the cavity and a second segment directly adjacent to and distal to the first segment, the second segment having a second diameter greater than that of the first diameter when: the distal end of the syringe is attached to the needle assembly, the needle assembly is primed such that the solution from the drug reservoir flows through the needle and is expelled from the distal end of the needle, and the slidable sleeve is in the first, distal position with respect to the needle hub. 2. The injector device of claim 1, wherein the input port comprises a luer connector. 3. The injector device of claim 2, wherein the luer connector comprises an internal luer seal. 4. The injector device of claim 3, wherein the internal luer seal comprises a proximal extension of the needle and is configured to open into the drug reservoir. 5. The injector device of claim 1, wherein the needle assembly further comprises a needle stabilization mechanism. 6. The injector device of claim 1, wherein the needle assembly comprises one or more filters. 7. The injector device of claim 1, wherein the needle assembly comprises a hydrophilic filter. 8. The injector device of claim 7, wherein the needle assembly further comprises a hydrophobic filter. 9. The injector device of claim 1, further comprising a needle deployment indicator. 10. The injector device of claim 9, wherein the needle deployment indicator comprises a high visibility dye. 11. The injector device of claim 6, wherein the one or more filters comprises a sterilizing filter. 12. The injector device of claim 11, wherein the sterilizing filter has pore sizes between 0.1 microns and 0.4 microns. 13. The injector device of claim 11, wherein the sterilizing filter comprises a low protein binding filter membrane. 14. The injector device of claim 13, wherein the sterilizing filter is located within the luer connector. 15. A system for delivering a pharmaceutical formulation into an eye comprising: the injector device of claim 1; and the drug reservoir. 16. The system of claim 15, wherein the drug reservoir comprises an active agent. 17. The system of claim 16, wherein the active agent comprises an anti-VEGF agent selected from the group consisting of ranibizumab, bevacizumab, aflibercept, and modifications, derivatives, and analogs thereof, and combinations thereof. 18. The system of claim 16, wherein the active agent comprises ranibizumab or bevacizumab. 19. The system of claim 16, wherein the active agent comprises aflibercept, ocriplasmin, a steroid, a placenta-derived growth factor, a platelet-derived growth factor, or combinations thereof. 20. The system of claim 16, wherein the active agent comprises an anti-complement agent, an anti-complement fraction agent, a complement-blocking agent, a complement-enhancing agent, a classic complement pathway inhibiting agent, an alternative complement inhibiting agent, a classic complement pathway potentiating agent, an alternative complement potentiating agent, or a combination thereof. 21. The injector device of claim 1, wherein the at least two segments of the priming-enabling component comprises a proximal segment with a narrower internal diameter and a distal segment with a wider internal diameter. 22. The injector device of claim 1, wherein the needle tunnel expands at its distal end to form a funnel or conical shape. 23. The injector device of claim 1, wherein the proximal segment of the at least two segments has a diameter that is the same as that of an outer diameter of the needle. 24. The injector device of claim 1, wherein the proximal segment of the at least two segments has a diameter that is within +/-0.12 mm of an outer diameter of the needle.

Details for Patent 9,504,603

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	February 26, 2004		2032-04-02
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	June 30, 2006		2032-04-02
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	August 10, 2012		2032-04-02
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	October 13, 2016		2032-04-02